;PMID: 8589724
;source_file_1227.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..181] = [t:36..181]
;2)section:[e:185..280] = [t:185..280]
;3)section:[e:284..381] = [t:284..381]
;4)sentence:[e:385..469] = [t:385..469]
;5)sentence:[e:470..657] = [t:470..657]
;6)sentence:[e:658..783] = [t:658..783]
;7)sentence:[e:785..915] = [t:785..915]
;8)sentence:[e:916..1079] = [t:916..1079]
;9)sentence:[e:1080..1258] = [t:1080..1258]
;10)sentence:[e:1259..1460] = [t:1259..1460]
;11)sentence:[e:1461..1585] = [t:1461..1585]
;12)sentence:[e:1586..1679] = [t:1586..1679]
;13)sentence:[e:1680..1762] = [t:1680..1762]
;14)section:[e:1766..1810] = [t:1766..1810]

;section 0 Span:0..31
;Nat Genet  1996 Mar;12(3):312-4
(SEC
  (FRAG (VBG:[0..3] Nat) (RB:[4..9] Genet) (CD:[11..15] 1996)
        (IN:[16..23] Mar;12-LRB-) (CD:[23..24] 3) (-RRB-:[24..25] -RRB-)
        (CD:[25..29] :312) (::[29..30] -) (CD:[30..31] 4)))

;sentence 1 Span:36..181
;Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive 
;mastocytosis: establishment of clonality in a human mast cell neoplasm.
;[44..49]:gene-rna:"c-KIT"
;[98..122]:malignancy:"aggressive  mastocytosis"
;[162..180]:malignancy:"mast cell neoplasm"
(SENT
  (NP-HLN
    (NP
      (NP
        (NP (JJ:[36..43] Somatic) (NN:[44..49] c-KIT) (VBG:[50..60] activating)
            (NN:[61..69] mutation))
        (PP (IN:[70..72] in)
          (NP (NN:[73..82] urticaria) (NN:[83..93] pigmentosa))))
      (CC:[94..97] and)
      (NP (JJ:[98..108] aggressive) (NN:[110..122] mastocytosis)))
    (::[122..123] :)
    (NP
      (NP (NN:[124..137] establishment))
      (PP (IN:[138..140] of)
        (NP (NN:[141..150] clonality)))
      (PP (IN:[151..153] in)
        (NP (DT:[154..155] a) (JJ:[156..161] human)
          
          (NML (NN:[162..166] mast) (NN:[167..171] cell))
          (NN:[172..180] neoplasm))))
    (.:[180..181] .)))

;section 2 Span:185..280
;Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P,
;Tang  LH, Modlin I.
(SEC
  (FRAG (NNP:[185..192] Longley) (NNP:[193..195] BJ) (,:[195..196] ,)
        (NNP:[197..204] Tyrrell) (NNP:[205..207] L,) (NNP:[208..210] Lu)
        (NNP:[211..213] SZ) (,:[213..214] ,) (NNP:[215..217] Ma)
        (NNP:[218..220] YS) (,:[220..221] ,) (NNP:[222..229] Langley)
        (NNP:[230..231] K) (,:[231..232] ,) (NNP:[233..237] Ding)
        (NNP:[238..240] TG) (,:[240..241] ,) (NNP:[242..247] Duffy)
        (NNP:[248..249] T) (,:[249..250] ,) (NNP:[251..257] Jacobs)
        (NNP:[258..259] P) (,:[259..260] ,) (NNP:[261..265] Tang)
        (NNP:[267..269] LH) (,:[269..270] ,) (NNP:[271..277] Modlin)
        (NNP:[278..280] I.)))

;section 3 Span:284..381
;Department of Dermatology, Yale University School of Medicine, New Haven 
;Connecticut 06510, USA.
(SEC
  (FRAG (NNP:[284..294] Department) (IN:[295..297] of)
        (NNP:[298..309] Dermatology) (IN:[309..310] ,) (NNP:[311..315] Yale)
        (NNP:[316..326] University) (NNP:[327..333] School) (IN:[334..336] of)
        (NNP:[337..345] Medicine) (,:[345..346] ,) (NNP:[347..350] New)
        (NNP:[351..356] Haven) (NNP:[358..369] Connecticut)
        (NNP:[370..375] 06510) (NNP:[375..376] ,) (NNP:[377..380] USA)
        (.:[380..381] .)))

;sentence 4 Span:385..469
;Mastocytosis is characterized by accumulations of mast cells in various
;organs  (1).
;[385..397]:malignancy:"Mastocytosis"
(SENT
  (S
    (NP-SBJ-1 (NN:[385..397] Mastocytosis))
    (VP (VBZ:[398..400] is)
      (VP (VBN:[401..414] characterized)
        (NP-1 (-NONE-:[414..414] *))
        (PP (IN:[415..417] by)
          (NP-LGS
            (NP (NNS:[418..431] accumulations))
            (PP (IN:[432..434] of)
              (NP (NN:[435..439] mast) (NNS:[440..445] cells)))
            (PP (IN:[446..448] in)
              (NP (JJ:[449..456] various) (NNS:[457..463] organs)
                (PRN (-LRB-:[465..466] -LRB-)
                  (NP (CD:[466..467] 1))
                  (-RRB-:[467..468] -RRB-))))))))
    (.:[468..469] .)))

;sentence 5 Span:470..657
;Most cases are indolent and confined to the skin, where discrete mast cell 
;infiltrates are associated increased epidermal melanin, a clinical picture
;known  as urticaria pigmentosa (UP).
;[593..600]:gene-protein:"melanin"
(SENT
  (S
    (NP-SBJ-1 (JJS:[470..474] Most) (NNS:[475..480] cases))
    (VP (VBP:[481..484] are)
      (UCP
        (ADJP-PRD (JJ:[485..493] indolent))
        (CC:[494..497] and)
        (VP (VBN:[498..506] confined)
          (NP-1 (-NONE-:[506..506] *))
          (PP (TO:[507..509] to)
            (NP
              (NP (DT:[510..513] the) (NN:[514..518] skin))
              (,:[518..519] ,)
              (SBAR
                (WHADVP-3 (WRB:[520..525] where))
                (S
                  (NP-SBJ-2 (JJ:[526..534] discrete)
                    (NML (NN:[535..539] mast) (NN:[540..544] cell))
                    (NNS:[546..557] infiltrates))
                  (VP (VBP:[558..561] are)
                    (VP (VBN:[562..572] associated)
                      (NP-2 (-NONE-:[572..572] *))
                      (NP (VBN:[573..582] increased) (JJ:[583..592] epidermal)
                          (NN:[593..600] melanin))
                      (,:[600..601] ,)
                      (NP-ADV
                        (NP (DT:[602..603] a) (JJ:[604..612] clinical)
                            (NN:[613..620] picture))
                        (VP (VBN:[621..626] known)
                          (NP (-NONE-:[626..626] *))
                          (PP-CLR (IN:[628..630] as)
                            (NP
                              (NP (NN:[631..640] urticaria)
                                  (NN:[641..651] pigmentosa))
                              (NP (-LRB-:[652..653] -LRB-) (NN:[653..655] UP)
                                  (-RRB-:[655..656] -RRB-))))))
                      (ADVP-LOC-3 (-NONE-:[656..656] *T*)))))))))))
    (.:[656..657] .)))

;sentence 6 Span:658..783
;Other forms of mastocytosis combine UP with  aggressive involvement of other
;organs or with haemotologic abnormalities (1-4).
;[673..685]:malignancy:"mastocytosis"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[658..663] Other) (NNS:[664..669] forms))
      (PP (IN:[670..672] of)
        (NP (NN:[673..685] mastocytosis))))
    (VP (VBP:[686..693] combine)
      (NP
        (NP (NN:[694..696] UP))
        (PP
          (PP (IN:[697..701] with)
            (NP
              (NP (JJ:[703..713] aggressive) (NN:[714..725] involvement))
              (PP (IN:[726..728] of)
                (NP (JJ:[729..734] other) (NNS:[735..741] organs)))))
          (CC:[742..744] or)
          (PP (IN:[745..749] with)
            (NP (JJ:[750..762] haemotologic) (NNS:[763..776] abnormalities)))))
      (PRN (-LRB-:[777..778] -LRB-)
        (NP (CD:[778..779] 1) (HYPH:[779..780] -) (CD:[780..781] 4))
        (-RRB-:[781..782] -RRB-)))
    (.:[782..783] .)))

;sentence 7 Span:785..915
;It is not known whether all forms of mastocytosis are true neoplasms or
;whether  some might represent reactive hyperplasias (5-7).
;[822..834]:malignancy:"mastocytosis"
;[844..853]:malignancy:"neoplasms"
;[887..908]:malignancy:"reactive hyperplasias"
(SENT
  (S
    (NP-SBJ-1
      (NP (PRP:[785..787] It))
      (SBAR-2 (-NONE-:[787..787] *EXP*)))
    (VP (VBZ:[788..790] is) (RB:[791..794] not)
      (VP (VBN:[795..800] known)
        (NP-1 (-NONE-:[800..800] *))
        (SBAR-2
          (SBAR (IN:[801..808] whether)
            (S
              (NP-SBJ
                (NP (DT:[809..812] all) (NNS:[813..818] forms))
                (PP (IN:[819..821] of)
                  (NP (NN:[822..834] mastocytosis))))
              (VP (VBP:[835..838] are)
                (NP-PRD (JJ:[839..843] true) (NNS:[844..853] neoplasms)))))
          (CC:[854..856] or)
          (SBAR (IN:[857..864] whether)
            (S
              (NP-SBJ (DT:[866..870] some))
              (VP (MD:[871..876] might)
                (VP (VB:[877..886] represent)
                  (NP
                     (JJ:[887..895] reactive) (NNS:[896..908] hyperplasias)
                    (PRN (-LRB-:[909..910] -LRB-)
                      (NP
                        (NP (CD:[910..911] 5))
                        (PP (HYPH:[911..912] -)
                          (NP (CD:[912..913] 7))))
                      (-RRB-:[913..914] -RRB-))))))))))
    (.:[914..915] .)))

;sentence 8 Span:916..1079
;The c-KIT proto-oncogene  encodes a type III receptor tyrosine kinase (KIT)
;that is critical to the  development and survival of mast cells and
;melanocytes (8-11).
;[920..925]:gene-rna:"c-KIT"
;[952..985]:gene-protein:"type III receptor tyrosine kinase"
;[987..990]:gene-protein:"KIT"
(SENT
  (S
    (NP-SBJ (DT:[916..919] The) (NN:[920..925] c-KIT) (AFX:[926..931] proto)
            (HYPH:[931..932] -) (NN:[932..940] oncogene))
    (VP (VBZ:[942..949] encodes)
      (NP
        (NP (DT:[950..951] a)
          (NML
            (NML
              (NML (NN:[952..956] type) (CD:[957..960] III))
              (NN:[961..969] receptor) (NN:[970..978] tyrosine)
               (NN:[979..985] kinase))
            (NML (-LRB-:[986..987] -LRB-) (NN:[987..990] KIT)
                 (-RRB-:[990..991] -RRB-))))
        (SBAR
          (WHNP-1 (WDT:[992..996] that))
          (S
            (NP-SBJ-1 (-NONE-:[996..996] *T*))
            (VP (VBZ:[997..999] is)
              (ADJP-PRD (JJ:[1000..1008] critical)
                (PP (TO:[1009..1011] to)
                  (NP
                    (NP (DT:[1012..1015] the) (NN:[1017..1028] development)
                        (CC:[1029..1032] and) (NN:[1033..1041] survival))
                    (PP (IN:[1042..1044] of)
                      (NP
                        (NP (NN:[1045..1049] mast) (NNS:[1050..1055] cells))
                        (CC:[1056..1059] and)
                        (NP (NNS:[1060..1071] melanocytes)
                          (PRN (-LRB-:[1072..1073] -LRB-)
                            (NP
                              (NP (CD:[1073..1074] 8))
                              (PP (HYPH:[1074..1075] -)
                                (NP (CD:[1075..1077] 11))))
                            (-RRB-:[1077..1078] -RRB-)))))))))))))
    (.:[1078..1079] .)))

;sentence 9 Span:1080..1258
;The ligand for  KIT (KL) can stimulate mast cell development, proliferation,
;and mediator  release (9,12-17), as well as melanocyte proliferation and
;pigment production  (18-20).
;[1096..1099]:gene-protein:"KIT"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (DT:[1080..1083] The) (NN:[1084..1090] ligand))
        (PP (IN:[1091..1094] for)
          (NP (NN:[1096..1099] KIT))))
      (NP (-LRB-:[1100..1101] -LRB-) (NN:[1101..1103] KL)
          (-RRB-:[1103..1104] -RRB-)))
    (VP (MD:[1105..1108] can)
      (VP (VB:[1109..1118] stimulate)
        (NP
          (NP
            (NP
              (NML-1 (NN:[1119..1123] mast) (NN:[1124..1128] cell))
              (NN:[1129..1140] development))
            (,:[1140..1141] ,)
            (NP
              (NML-1 (-NONE-:[1141..1141] *P*))
              (NN:[1142..1155] proliferation))
            (,:[1155..1156] ,) (CC:[1157..1160] and)
            (NP
              (NML-1 (-NONE-:[1160..1160] *P*))
              (NN:[1161..1169] mediator) (NN:[1171..1178] release))
            (PRN (-LRB-:[1179..1180] -LRB-)
              (NP
                (NP (CD:[1180..1181] 9))
                (,:[1181..1182] ,)
                (NP
                  (NP (CD:[1182..1184] 12))
                  (PP (HYPH:[1184..1185] -)
                    (NP (CD:[1185..1187] 17)))))
              (-RRB-:[1187..1188] -RRB-)))
          (,:[1188..1189] ,)
          (CONJP (RB:[1190..1192] as) (RB:[1193..1197] well)
                 (IN:[1198..1200] as))
          (NP
            (NP (NN:[1201..1211] melanocyte) (NN:[1212..1225] proliferation))
            (CC:[1226..1229] and)
            (NP (NN:[1230..1237] pigment) (NN:[1238..1248] production)
              (PRN (-LRB-:[1250..1251] -LRB-)
                (NP
                  (NP (CD:[1251..1253] 18))
                  (PP (HYPH:[1253..1254] -)
                    (NP (CD:[1254..1256] 20))))
                (-RRB-:[1256..1257] -RRB-)))))))
    (.:[1257..1258] .)))

;sentence 10 Span:1259..1460
;To determine the role of c-KIT in the pathogenesis of mastocytosis, we 
;examined tissue and cells isolated from a patient with UP and aggressive 
;systemic mastocytosis with massive splenic involvement.
;[1284..1289]:gene-rna:"c-KIT"
;[1313..1325]:malignancy:"mastocytosis"
;[1393..1426]:malignancy:"aggressive  systemic mastocytosis"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1259..1259] *))
      (VP (TO:[1259..1261] To)
        (VP (VB:[1262..1271] determine)
          (NP
            (NP (DT:[1272..1275] the) (NN:[1276..1280] role))
            (PP (IN:[1281..1283] of)
              (NP (NN:[1284..1289] c-KIT)))
            (PP (IN:[1290..1292] in)
              (NP
                (NP (DT:[1293..1296] the) (NN:[1297..1309] pathogenesis))
                (PP (IN:[1310..1312] of)
                  (NP (NN:[1313..1325] mastocytosis)))))))))
    (,:[1325..1326] ,)
    (NP-SBJ (PRP:[1327..1329] we))
    (VP (VBD:[1331..1339] examined)
      (NP
        (NP (NN:[1340..1346] tissue) (CC:[1347..1350] and)
            (NNS:[1351..1356] cells))
        (VP (VBN:[1357..1365] isolated)
          (NP (-NONE-:[1365..1365] *))
          (PP-CLR (IN:[1366..1370] from)
            (NP
              (NP (DT:[1371..1372] a) (NN:[1373..1380] patient))
              (PP (IN:[1381..1385] with)
                (NP
                  (NP (NN:[1386..1388] UP))
                  (CC:[1389..1392] and)
                  (NP
                    (NP (JJ:[1393..1403] aggressive) (JJ:[1405..1413] systemic)
                        (NN:[1414..1426] mastocytosis))
                    (PP (IN:[1427..1431] with)
                      (NP (JJ:[1432..1439] massive) (JJ:[1440..1447] splenic)
                          (NN:[1448..1459] involvement)))))))))))
    (.:[1459..1460] .)))

;sentence 11 Span:1461..1585
;We found a mutation that  results in constitutive activation and expression
;of c-KIT in mast cells of both  skin and spleen.
;[1540..1545]:gene-rna:"c-KIT"
(SENT
  (S
    (NP-SBJ (PRP:[1461..1463] We))
    (VP (VBD:[1464..1469] found)
      (NP
        (NP (DT:[1470..1471] a) (NN:[1472..1480] mutation))
        (SBAR
          (WHNP-1 (WDT:[1481..1485] that))
          (S
            (NP-SBJ-1 (-NONE-:[1485..1485] *T*))
            (VP (VBZ:[1487..1494] results)
              (PP-CLR (IN:[1495..1497] in)
                (NP
                  (NP
                    (NP (JJ:[1498..1510] constitutive)
                        (NN:[1511..1521] activation))
                    (CC:[1522..1525] and)
                    (NP (NN:[1526..1536] expression)))
                  (PP (IN:[1537..1539] of)
                    (NP (NN:[1540..1545] c-KIT)))))
              (PP (IN:[1546..1548] in)
                (NP
                  (NP (NN:[1549..1553] mast) (NNS:[1554..1559] cells))
                  (PP (IN:[1560..1562] of)
                    (NP (CC:[1563..1567] both) (NN:[1569..1573] skin)
                        (CC:[1574..1577] and) (NN:[1578..1584] spleen))))))))))
    (.:[1584..1585] .)))

;sentence 12 Span:1586..1679
;This is the first in situ demonstration of an activation c-KIT  mutation in
;neoplastic cells.
;[1643..1648]:gene-rna:"c-KIT"
(SENT
  (S
    (NP-SBJ (DT:[1586..1590] This))
    (VP (VBZ:[1591..1593] is)
      (NP-PRD
        (NP (DT:[1594..1597] the) (JJ:[1598..1603] first)
          (ADJP (FW:[1604..1606] in) (FW:[1607..1611] situ))
          (NN:[1612..1625] demonstration))
        (PP (IN:[1626..1628] of)
          (NP
            (NP (DT:[1629..1631] an) (NN:[1632..1642] activation)
                (NN:[1643..1648] c-KIT) (NN:[1650..1658] mutation))
            (PP (IN:[1659..1661] in)
              (NP (JJ:[1662..1672] neoplastic) (NNS:[1673..1678] cells)))))))
    (.:[1678..1679] .)))

;sentence 13 Span:1680..1762
;It also demonstrates the clonal and neoplastic  nature of this form of
;mastocytes.
(SENT
  (S
    (NP-SBJ (PRP:[1680..1682] It))
    (ADVP (RB:[1683..1687] also))
    (VP (VBZ:[1688..1700] demonstrates)
      (NP
        (NP (DT:[1701..1704] the)
          (ADJP (JJ:[1705..1711] clonal) (CC:[1712..1715] and)
                (JJ:[1716..1726] neoplastic))
          (NN:[1728..1734] nature))
        (PP (IN:[1735..1737] of)
          (NP
            (NP (DT:[1738..1742] this) (NN:[1743..1747] form))
            (PP (IN:[1748..1750] of)
              (NP (NNS:[1751..1761] mastocytes)))))))
    (.:[1761..1762] .)))

;section 14 Span:1766..1810
;PMID: 8589724 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1766..1770] PMID) (::[1770..1771] :) (CD:[1772..1779] 8589724)
        (NN:[1780..1781] -LSB-) (NNP:[1781..1787] PubMed) (::[1788..1789] -)
        (NN:[1790..1797] indexed) (IN:[1798..1801] for)
        (NNP:[1802..1810] MEDLINE-RSB-)))
